Dr. Ajay K. Nangia is Professor of Urology at the University of Kansas Medical Center. Dr. Nangia received his medical degree from St. Thomas and Guy's Hospital Medical School in London, U.K. He completed 2 years of research at Yale University prior to residency. He completed his Urology residency at the University of Pittsburgh Medical Center and a Male Infertility and Microsurgery fellowship at the Cleveland Clinic Foundation in Cleveland, Ohio. Dr. Nangia was at Dartmouth-Hitchcock Medical Center in New Hampshire prior to coming to Kansas and the Kansas City area. Dr Nangia is a fellowship trained male infertility specialist in the metropolitan Kansas City area with 14 years of experience and national involvement in the field. He is one of the leading male infertility specialists nationally and the Kansas, Missouri and the Midwest region. He has an extensive experience in male infertility, urological microsurgical reconstruction including vasectomy reversals in the Kansas, Western Missouri, Oklahoma and Nebraska region. He also specializes in Men's Health issues as they relate to sexual and reproductive health especially male contraception, testosterone deficiency, erectile dysfunction and ejaculatory problems. He and Dr Broghammer have one of the largest practices in surgical correction for erectile dysfunction (penile prostheses) in the region. He also specializes in fertility and sexual dysfunction issues related to spinal cord injuries and pre and post cancer treatment.. Dr Nangia is a leading national specialist in the field of vasectomies and complications from vasectomies. He also has a secondary specialty in stone disease.
Dr. Nangia was in the 2010 Leadership Class for the American Urological Association; President Elect of the Society of Male Reproduction and Urology and on the Residency Education Committee of the American Society of Reproductive Medicine. He is also on the Research Committee of the Society for Assisted Reproductive Technology (SART). He is a member of the American College of Surgeons. He is past Chair of the Ethics Committee of the American Society of Andrology, and Past-President of the Society for the Study of Male Reproduction (a branch of the American Urological Association), to name a few. He is also a liaison with the CDC (Center for Disease Control) for male reproduction. He has been named Top Urologist by the Consumer Research Council in 2007, 2009 and 2010; Best Doctors in Kansas City (KC Business Journal) 2011-2014 and America in 2010 and nominated to Who's Who in America in 2010- 2014.
He has written several peer-reviewed journal articles in the field of urology including male infertility, vasectomy reversal microsurgery, vasectomy, and a member of the Best Practice Statement for Male Infertility and also Azoospermia by the American Urological Association (AUA). He is currently on the AUAs male sexual function guidelines panel and testosterone position statement panel. He is a member of the AUAs Men's Health Initiative which is developing men's health recommendations for men ages 18 and up. He also serves on the AUA Health Policy Council and Public Media Committee. He educates community providers, patients and high school students in the community on issues of male reproductive and sexual health. He reviews for a number of urology and fertility journals and has lectured internationally, nationally and regionally. He is the Clinical Director of Andrology at the University of Kansas Medical Center and President of the Kansas Urological Society. Dr. Nangia's special interests in the field of urology are micro-surgical reconstruction including vasectomy reversal, male infertility, vasectomy/male contraception and male sexual/reproductive dysfunction, and is actively involved with research in male contraception, as well as the study of vitamin D in sperm/testicular physiology.
He is Co-Principal Investogator on cutting edge research and development of a reversible male contraceptive through the Male Contraceptive Trials Network. He is also involved with on-going research in the development of a non-hormonal reversible male contraception that is very promising and may go into clinical trials in the next few years.